Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead
Compugen Ltd (CGEN) reported Q3 2026 revenue of $3.8M, doubling from the prior year. CEO Dr. Eran Ophir discussed milestones with AstraZeneca and Gilead, including potential payments and clinical trial updates. The company has $117.5M in cash and expects funding into 2029. Clinical trials for COM701 and GS-0321 are progressing, with data expected in 2027.


